8-K: Recursion Pharmaceuticals Holds Annual Meeting, Elects Directors
Annual Meeting Results
Recursion Pharmaceuticals, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and the ratification of its independent auditor.
Summary
- Recursion Pharmaceuticals, Inc. held its 2026 Annual Meeting of Stockholders on June 17, 2026.
- Stockholders elected two Class II directors, Najat Khan, Ph.D. and Franziska Michor, Ph.D., to serve until the 2029 annual meeting.
- The advisory resolution to approve executive compensation was approved.
- The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026, was ratified.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it reports on standard annual meeting proceedings without introducing new financial performance data or strategic initiatives.
Positives
- Directors Najat Khan, Ph.D. and Franziska Michor, Ph.D. were elected with significant support.
- The advisory resolution to approve executive compensation passed with a majority of votes.
- The appointment of PricewaterhouseCoopers LLP as the independent auditor was ratified with overwhelming support.
Future Outlook
No specific future outlook or guidance was provided in this filing, which pertains to the results of the annual meeting.
Industry Context
StockSavvy.ai notes that the routine nature of this 8-K filing, detailing annual meeting outcomes, is common for publicly traded companies and typically does not signal significant strategic shifts or financial performance changes on its own.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Class II Director | N/A | Najat Khan, Ph.D. | June 17, 2026 | Elected by stockholders |
| Class II Director | N/A | Franziska Michor, Ph.D. | June 17, 2026 | Elected by stockholders |
Stakeholder Impact
- Shareholders: The election of directors and approval of executive compensation directly impact shareholder representation and oversight.
- Employees: The ratification of the auditor and approval of compensation indirectly affect employee confidence and company operations.
- Creditors: The stability indicated by routine governance procedures can positively influence creditor confidence.
Key Dates
| Date | Description |
|---|---|
| April 30, 2026 | Date of filing of the Company's definitive Proxy Statement for the Annual Meeting. |
| June 17, 2026 | Date of the 2026 Annual Meeting of Stockholders. |
| June 17, 2029 | Term end date for elected Class II directors. |
| December 31, 2026 | Fiscal year for which PricewaterhouseCoopers LLP was appointed as independent auditor. |
| June 18, 2026 | Date of the report signature. |
Keywords
Recursion Pharmaceuticals, Annual Meeting, Stockholder Vote, Director Election, Executive Compensation, Independent Auditor, PricewaterhouseCoopers LLP, Form 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.